Tsionizm
Science & Technology

14 Of 16 Severe COVID Patients In Trial Recover With Experimental Israeli Drug

Reuven Rivlin with the first vaccinator in Phase B of the Israeli Vaccine of the Israeli Biological Institute, January 2021
Image by Amos Ben Gershom

Please Follow us on GabParlerMindsTelegram

Israeli immunotherapy company Enlivex Therapeutics said Wednesday that 16 severe and critical COVID-19 patients who received its experimental treatment had survived a 28-day Phase II clinical trial period.

Two of the patients, who were critical cases at the start of the trial when they received the company’s Allocetra treatment, were still in intensive care and on ventilators at the end of the trial.

The other 14 patients recovered, were discharged from the hospital by the end of the trial and were reported to be healthy. The average duration of hospitalization after receiving Allocetra, for those who were discharged, was 5.3 days, the company said…

To read more visit The Times Of Israel.

CDMedia’s bank accounts were recently wiped by Deep State fraud. We need your support to put more reporters in the field! Help us here! 

Related articles

Israeli Lunar Lander Beresheet Successfully Completes Maneuver To Capture Moon Orbit Sends Another Shot Of Earth

Baruch Pletner

Is There any Doubt Now That Israel Is Destroying Itself? Citizens Told To Get Ready For 4th Shot

Tsionizm Staff

Hero Dr. Zelenko Calls Into Steve Bannon’s War Room: Pandemic To Discuss Chloroquine Trials

Tsionizm Staff

Leave a Comment

Subscribe to our evening newsletter to stay informed during these challenging times!!